TATT · Desk conversation

At 17:55 UTC, the S&P 500, Nasdaq 100 and Russell 2000 were modestly higher, while the VIX rose. The 10-year yield and dollar fell; gold rose as WTI fell. That is selective strength, not a clean risk-on session. The intraday breadth proxy leaned positive, but the EOD reading was unavailable.

The seven-row market snapshot is complete. The breadth proxy was mostly fresh but had one stale quote, and it is still only an intraday view. The shared news brief had no items. None of that ranks a company or blocks a bounded comparison.

TATT has the clearest event-and-tape combination: the packet reports a record Q3, with +14.78% on 2.30 times average volume. It was above the captured $36.04 VWAP—the session's average price weighted by trading activity—though its later in-cut return eased.

Supplied coverage reports EPS of $0.58 against $0.40 and sales of $55.563 million against $52.752 million. Three 6-K filing records landed before the cut. That is a specific results event to follow, not proof that every figure has been reconciled to the filings.

Right. The filing records establish that documents were filed; their titles do not validate those detailed numbers. The SEC fundamentals snapshot ends December 31, 2025, so it cannot verify this November 2026 quarter.

TATT is 1.80 ATR above its EMA reference. ATR is its typical daily price range; 1.80 means the price is well beyond one usual day's movement from that reference, so a pullback could matter. The move also eased in the later capture.

Against XLI, an industrials-sector fund proxy, TATT was ahead by 8.69 percentage points over 20 sessions. That relative lead is useful, but it does not erase the later easing or prove the next 30 sessions.

IDXX is the serious alternative: +26.72% over 20 sessions versus +10.26% for XLV, but it sits 3.87 ATR above its EMA reference, its intraday slope was negative, and supplied coverage also mentions a lower margin outlook. Stronger relative return; less balanced continuation evidence.

I dissent from Try of the Day. The reported figures have not been reconciled to the filed content, and the model's 15-session positive-return probability is 0.496967 on eight comparable cases. Its adverse-move P10 is −23.03%. That wide tail is a real reservation; I would call this Raw Try until the source detail is checked.

That model estimate is context, not a vote: it has eight comparable cases, and its SEC-aware snapshot is dated September 1 without point-in-time validation. I still support Try for TATT because the dated results event and relative market response are present; the missing reconciliation stays visible.

I support TATT over the other tapes. ZG has a strong relative path but its program's financial effect is not measured; CHH's supplied guidance headlines remain unresolved. TATT's path is not clean, but its event and participation are more directly connected.

I support Try with the stated reservation. If the 6-K details fail to support the reports, or follow-up loses the captured VWAP and relative advantage, the continuation case is broken. That is a testable failure condition, not a promise.

The formal resolution is Try of the Day for TATT, with Elena's Raw Try dissent recorded. The case earns the selection through the reported results and market response; the filing reconciliation, extension and adverse range remain open.

Reopen: Please describe 0.497 as a model estimate without attributing an eight-case sample to it; that count belongs to separate historical outputs. Trim the comparison to TATT and its four strongest alternatives, using only market observations available by the review cutoff.

That attribution was wrong. About 0.497 is the model's 15-session positive-return estimate, and its output gives no sample count. Eight belongs to separate historical adverse-move and return-dispersion outputs. The estimate is near even odds, not a decisive edge. Separately, the SEC-aware adverse-MAE estimate—the modeled largest decline from entry—has an H15 P10 of −23.03% and median of −10.66%; its SEC snapshot is dated September 1 and lacks confirmed point-in-time validity.

The public comparison is now TATT, IDXX, ZG, CHH, and BR. I removed the post-cut 20-session figures. CHH and BR remain only on their dated event records and provider observations available by 17:57:17 UTC; their later captures do not enter this comparison.

My dissent remains Raw Try: until the reported results are reconciled, I would keep the case more conditional. The correction does not change the evidence or reopen the selection.

I retain Try of the Day. The reported event, elevated activity, and positive relative path give us a specific thesis and a filing check; the unreconciled figures stay clearly labeled.

I retain Try with the risk stated plainly. The model estimate does not cancel the modeled adverse tail, and the captured $36.04 VWAP and relative performance are follow-up checks, not guarantees.